BLUETTI to Release AC180, Making Another Breakthrough in Portable Power Station Area
21.4.2023 13:16:00 EEST | Business Wire | Press release
Spring camping has gradually become popular in recent years, providing a precious chance for people to get rid of the hustle and bustle of urban life and have close contact with nature. However, most of their trips experienced mobile power shortages out there.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230421005196/en/
(Photo: Business Wire)
BLUETTI, a market leader in the energy storage industry, is about to unveil a brand-new model. As a successor of the previous portable stations such as EB150 and EB240, AC180 is designed with a bunch of improvements that kit it up a notch, making it a well-deserved portable power station for emergency backup, sudden blackouts, excursions, and more.
Explore Outdoors with Great Capacity
To help elevate the off-grid lifestyle, BLUETTI equips AC180 with a 1800W constant output power and 1.152Wh capacity, covering almost all power demands of essentials at home or in the wild. Furthermore, AC 180 also comes with a Power Lifting Mode of 2.700W output to effortlessly run high-powered devices like kettles, hair dryers, microwaves, etc.
Besides, AC180 is updated with a 1,7-inch LCD display and bigger font size to make the power consumption and troubleshooting status more visualized and clearly.
Travel with Grab-and-go Power
Pack lighter, travel further. In view of portability, AC180 is ultra compact for effortless transportation as it measures 340mmx247mmx317mm (H x W x H) and weighs only 35kg. It does not occupy too much space of the truck on the way to the next campsite.
Recharge with High Speed
For outdoor enthusiasts looking for backup power for their camping or RV trips on the road, AC180 is sure to exceed their expectations. Even exploring off the beaten track far from the main grid, the reliable power source is always on call as AC180 supports up to 1.440W Turbo Charging, 0-80% SOC only takes about 45mins! Get it charged before packing up for the getaway, a large amount of power is ready to hit the road when you are.
Live with Uninterrupted Power Supply
Given the UPS system, there’s no need to worry about losing data or hardware damage in the event of a power outage since AC180 can automatically detect the blackout the moment it occurs and seamlessly switch over in 20ms that no one can even be aware of.
Constant Power with Peace of Mind
Keeping high security and longevity in mind, BLUETTI adopts safe and durable LiFePO4 battery cells and guarantees a worry-free warranty for as long as 5 years, which really sets it apart from most competitors throughout the market.
Remotely monitoring AC180 in real time is a no-brainer thanks to the intelligent BLUETTI APP. Now setting up working modes, checking the system conditions, and OTA updates can be done solely with fingertips.
“We’re dedicated to more innovations that’s a right fit for the increasing market demand. Our R&D team once envisioned a power station integrated with portability, capability, and cost performance, and now we’ve made it come true. AC180 has everything users could possibly need without costing an arm and a leg,” said James Ray, the marketing director of BLUETTI.
Availability
Though the debut price is not finally decided yet, it’s believed to be the most affordable power station that worth the wait.
About BLUETTI
From the very beginning, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for our homes and our world. That's why BLUETTI makes its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online at https://www.bluettipower.eu/ or follow BLUETTI on:
YouTube: https://www.youtube.com/c/bluettiofficial
Facebook: https://www.facebook.com/bluettipower.eu/
Twitter: https://twitter.com/bluetti_inc
Instagram: https://www.instagram.com/bluetti_europe/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230421005196/en/
Contact information
jacinda@bluetti.com
130 4085 7737
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
